JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

Home・Aandelen Lijst・Cogent Biosciences Inc

Cogent Biosciences Inc

Gesloten

12.08 -0.33

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

11.92

Max

12.13

Belangrijke statistieken
By Trading Economics
Inkomsten	-4.1M -72M
Werknemers	205
EBITDA	-1.2M -74M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+62.72% upside

Dividenden
By Dow Jones
Volgende Winsten	5 aug 2025

Marktinformatie
By TradingEconomics
Marktkapitalisatie	1.1B 1.7B
Vorige openingsprijs	12.41
Vorige sluitingsprijs	12.08

Technische score

By Trading Central

Vertrouwen

Bearish Evidence

4.88 / 5.87 Steun & Weerstand

Cogent Biosciences Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

25 jul 2025, 17:53 UTC

Belangrijke Marktbewegers

Genworth Shares Rise On UK Court Ruling That Could Lead to $750 Million Windfall

25 jul 2025, 15:58 UTC

Winsten

Belangrijke Marktbewegers

Aon Shares Rise After 2Q Earnings Beat

25 jul 2025, 15:08 UTC

Belangrijke Marktbewegers

AST SpaceMobile Shares Slide After Convertible Notes, Stock Offerings

25 jul 2025, 21:40 UTC

Marktinformatie

Starbucks' Spending Hikes Are Misdirected -- Market Talk

25 jul 2025, 21:23 UTC

Marktinformatie

Honeywell's Growth Seen Holding Up Despite Recent Headwinds -- Market Talk

25 jul 2025, 20:40 UTC

Winsten

Tesla Stock Is Rising. Robo-taxi Trumps a Lack of New Models. -- Barrons.com

25 jul 2025, 20:10 UTC

Winsten

These Stocks Moved the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25 jul 2025, 19:56 UTC

Winsten

Correction to Why Bargain Hunters Are Flocking to 'Bin Stores' -- Barrons.com on July 20

25 jul 2025, 19:14 UTC

Marktinformatie

Oil Futures Post Back-to-Back Weekly Losses -- Market Talk

25 jul 2025, 19:10 UTC

Marktinformatie

U.S. Natural Gas Futures Appear to Stabilize -- Market Talk

25 jul 2025, 19:01 UTC

Winsten

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25 jul 2025, 18:45 UTC

Marktinformatie

Gold Ends Down Week on Lower Note -- Market Talk

25 jul 2025, 18:35 UTC

Acquisities, Fusies, Overnames

Sale Could Fetch Around $1B, Sources Say -- WSJ

25 jul 2025, 18:35 UTC

Acquisities, Fusies, Overnames

LVMH in Talks to Sell Marc Jacobs -- WSJ

25 jul 2025, 18:35 UTC

Acquisities, Fusies, Overnames

Suitors for Marc Jacobs Include Authentic, Bluestar Alliance and WHP Global, Sources Say -- WSJ

25 jul 2025, 18:35 UTC

Acquisities, Fusies, Overnames

LVMH Exploring Sale of Fashion Brand Marc Jacobs, Sources Say -- WSJ

25 jul 2025, 17:38 UTC

Belangrijke Marktbewegers

Genworth Shares Rise On UK Court Ruling That Could Lead to $750M Windfall

25 jul 2025, 17:26 UTC

Marktinformatie

U.S. Oil Rig Count Extends Decline -- Market Talk

25 jul 2025, 17:13 UTC

Winsten

Tesla Stock Is Rising. Robo-taxi Trumps a Lack of New Models. -- Barrons.com

25 jul 2025, 16:46 UTC

Winsten

Volkswagen Teases Made-in-America Audis, Porsches After $1.5 Billion Tariff Hit -- 2nd Update

25 jul 2025, 16:45 UTC

Winsten

Apple Earnings Are Next Week. Why This Analyst Says Be Cautious. -- Barrons.com

25 jul 2025, 16:27 UTC

Winsten

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25 jul 2025, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

25 jul 2025, 16:02 UTC

Winsten

Acquisities, Fusies, Overnames

Berkshire Stock Is Losing Its Buffett Premium. Now Is the Time to Buy. -- Barrons.com

25 jul 2025, 15:34 UTC

Winsten

Intel's Harsh Reality Nullifies Tariff Boost -- WSJ

25 jul 2025, 15:06 UTC

Marktinformatie

Base Metal Prices Fall on Stronger U.S. Dollar -- Market Talk

25 jul 2025, 15:05 UTC

Winsten

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Comfort Systems, and More -- Barrons.com

25 jul 2025, 14:45 UTC

Marktinformatie

Oil Rangebound Amid U.S.-EU Trade Uncertainty -- Market Talk

25 jul 2025, 14:44 UTC

Marktinformatie

Gold Futures Set to End Week Lower on Easing Trade War Concerns -- Market Talk

25 jul 2025, 14:36 UTC

Marktinformatie

Winsten

Phillips 66 CEO Says California Administration Supports of LA Plant Closure -- Market Talk

Peer Vergelijking

Prijswijziging

Cogent Biosciences Inc Prognose

Koersdoel

By TipRanks

62.72% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 19.64 USD 62.72%

Hoogste 29 USD

Laagste 9 USD

Gebaseerd op 12 Wall Street-analisten die 12-maands prijsdoelen bieden voor Cogent Biosciences Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

12 ratings

Buy

Hold

Sell

Gebaseerd op 12 analisten die aandelenratings hebben gegeven aan Cogent Biosciences Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

4.88 / 5.87Steun & Weerstand

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.